CORRECTION

Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy

Francesco P. Schena\textsuperscript{1,2}, Giovanni Tripepi\textsuperscript{3}, Michele Rossini\textsuperscript{4}, Daniela I. Abbrescia\textsuperscript{2} and Carlo Manno\textsuperscript{1}

\textsuperscript{1}Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, \textsuperscript{2}Fondazione Schena, Policlinic, Bari, Italy, \textsuperscript{3}CNR-IFC, Institute of Clinical Physiology, Reggio Calabria, Italy and \textsuperscript{4}Ospedale Consorziale, Policlinic, Bari, Italy

Correspondence to: Francesco P. Schena; E-mail: paolo.schena@uniba.it

In the original publication of this article, text showed that outcome measures and statistical analysis will be assessed at 3 months in the ACIgAN study. Now 3 months has been corrected to 6 months. Primary endpoint assessment will be done at 6 months in the ACIgAN study and at 12 months in CHRONIgAN study.